NCT04916080View on ClinicalTrials.gov

N-acetyl Cysteine: the Effectiveness and Safety in a Cohort of Pediatric Patients With Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

January 1, 2023

Conditions
Chronic Kidney Diseases
Interventions
DRUG

N-acetyl cysteine

mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally

Trial Locations (2)

65211

Beni-Suef university hospital, Banī Suwayf

Unknown

Pediatric nephrology and transplantation unite.Aboelrish children hospital, Cairo

All Listed Sponsors
collaborator

Cairo University

OTHER

lead

Beni-Suef University

OTHER

NCT04916080 - N-acetyl Cysteine: the Effectiveness and Safety in a Cohort of Pediatric Patients With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter